27.6 C
Istanbul
Sunday, June 16, 2024

Textilegence May June 2024 has been published

Textilegence May June 2024 issue brings to...

BRÜCKNER celebrates its 75 years of tradition and innovation in textile

This year, the German family-run company BRÜCKNER...

Italian textile machinery orders remain stationary for first quarter 2024

For the Italian textile machinery sector, the...

Bego Jeans; the story of clean denim

Bego Jeans implements a sustainable and clean...

How does Russia-Ukraine War affect Turkish textile industry?

The tension between Russia and Ukraine for...

Itema and Tofflon’s new joint venture in pharmaceutical: Tofflonit

TopicalItema and Tofflon’s new joint venture in pharmaceutical: Tofflonit

-News Sponsor -

Itema, one of the leading global providers of advanced weaving solutions, and Tofflon Science and Technology Group Co. Ltd., Asiatic giant company in the pharmaceutical industry, have presented their new joint venture Tofflonit. The new company, dedicated to the production of industrial lyophilizers for the biopharmaceutical sector, operates under the name Tofflon Itema Srl. With an initial investment of 10 million euros, the company will have its regional headquarters in Nibbia, in the province of Novara, where a manufacturing plant with high quality and innovation levels has been operating since October. The agreement was illustrated in Bergamo on October 24th during BioTopics 2023, the event dedicated to biotechnologies and open innovation.

Founded in Shanghai in 1993, Tofflon is a comprehensive pharmaceutical equipment supplier to provide process support, core equipment, integrated systems and pharma engineering for the pharma and biotech industry, with more than 5,800 employees worldwide and a 2022 turnover of about 800 million US dollars. In order to pursue its strategy of internationalization and expansion, the group chose Itema as the partner for the planning and engineering of its new branch in Europe, where the group will produce lyophilization systems for the production of antibiotics, vaccines, diagnostic drugs, products containing proteins and biotechnological products.

Tofflon Science and Technology Group Co. Ltd. Senior Vice President Michael Chang disclosed that throughout their thirty-year activity, they have developed solid skills for the production of machinery and equipment for the pharmaceutical and biotech industry, saying: “Our aim is to further grow in the European and American markets, approaching clients to whom we want to ensure the excellence of our solutions with efficient services and ideal shipping times. We are sure that the collaboration with Itema will enable us to reach excellent results.”

Itema ve Tofflon’un ilaç sektöründeki yeni ortak girişimi: Tofflonit  Görsel Kaynak: Itema
Tofflonit represents another significant step of Itema Group diversification strategy  Image Source: Itema

Tofflonit represents another significant step of Itema Group diversification strategy 

Known in the world for its weaving machines and integrated solutions, Itema has transferred its experience in mechanical, electronic, and mechatronic technologies to Itemalab, founding a multidisciplinary hub that in the last few years has become a privileged partner for companies in any industrial sector that need advice and support in innovation and sustainability, from digitalization to system engineering.

CEO of Itema Ugo Ghilardi commented regarding the new joint venture: “We are proud that Tofflon selected Itemalab to fine-tune the industrial plan that will bring to the market its advanced lyophilization systems. The factory of Tofflonit in Nibbia is a clear demonstration of the skills of Itemalab in the fields of lean manufacturing and open innovation, and it represents another significant step of our Group diversification strategy after the takeover of Lamiflex, the leading supplier of composite products.”

Check out the other news

Authors other news

Most read news